abdominal pain care plans

Posted by on 31 December, 2009
No comments yet
This item was filled under [ Most Popular ]

Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010
In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (
ZezO-Do You Care

Be Sociable, Share!
Tags:
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
«
»



#